Investment Thesis
- Ageing Population Requires more diagnostic tests especially as medicine focuses on Preventives medicine
- Market leading positions in Pathology(number one in Australia, Germany, Switzerland and United Kingdom number three in US). Australia is the Second leading player in the market in Imaging.
- Establishment of Global Channels to high barriers entry.
- Organic growth and potential improvement from margin cost strategy on the acquisition of ongoing bolt.
- Leveraged against a weakening dollar.
- Globally Diversified.
Key Risks
- Diagnostic expenses are being decreased as a result of disruptive technology.
- Market share is being lost due to competitive threats.
- Deregulation has resulted in the establishment of new pathology collection centres.
- Regulative changes that are detrimental (fee cuts).
- Growth that has been disappointing.
- Unfavorable currency fluctuations (AUD, EUR, USD).
FY21 results highlights
- Revenue Growth of +28 to A$8.8 billion. In constant Currency, revenue of $9,129 million was up +33.7%, driven by Covid-19 testing revenue in each of SHL’s laboratory businesses. Base business revenue (exclude Covid testing) grew +6% versus FY20 and +4% versus FY19.
- EBITDA growth of +81% to A$ 2.6 Billion (or +89% on constant Currency basis) driven by +97% EBITDA Growth of +89% in the laboratory division due to Covid-19 testing.
- Net profit growth of +149% to A$1.3 billion, reflecting growth in revenue and SHL’s strong operating leverage.
- Sonic Healthcare achieved margin accretion in both laboratory and imaging divisions.
- SHL’s balance sheet is well placed with record low gearing level and liquidity of ~A$1.5bnto fund growth via acquisitions.
- Gearing (Net debt/[Net debt + equity) of 12.5%, interest cover (EBITA/Net interest expense) of 33.8x and debt cover (Net debt/EBITDA) of 0.4x all improved from 21.6%, 20.5x and 1.0x, respectively, at Dec-20 (and remains within covenant limit of <55%, >3.25x, and <3.5x respectively).
- As per its progressive dividend policy, sonic healthcare declared a final dividend of 55cps, up +8% and franked to 65%. Total dividends are up +7%.
Company Profile
Sonic Healthcare (SHL) is a medical diagnostics company with operations in Australia, New Zealand, and Europe. The company provides a comprehensive range of pathology and diagnostic imaging services to medical practitioners, hospitals and their patients along with providing administrative services and facilities to medical practitioners. SHL has three main segments: (1) Pathology/clinical laboratory services based in Australia, NZ, UK, US, Germany, Switzerland, Belgium and Ireland. (2) Diagnostic imaging services in Australia; and (3) Other which includes medical centre operations (IPN), occupational health services (Sonic HealthPlus) and laboratory automation development (GLP Systems).
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.